Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multidrug Resistance Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

NCT06258551
View directory record Official record
Conditions
Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection, Extended Spectrum Beta-Lactamase Producing Bacteria Infection, Vancomycin Resistant Enterococci Infection, Carbapenem Resistant Bacterial Infection, Vancomycin-Resistant Enterococcal Infection
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

NCT00001302
View directory record Official record
Conditions
Breast Cancer, Kidney Neoplasm, Lymphoma, Neoplasm Metastasis, Ovarian Cancer
Interventions
PSC 833
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Phase 2 Interventional

A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection

NCT00001339
View directory record Official record
Conditions
Adrenal Cortical Carcinoma
Interventions
doxorubicin, vincristine, and etoposide with mitotane
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 11:05 AM EDT
Active, not recruiting No phase listed Observational

Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia

NCT00898456
View directory record Official record
Conditions
Leukemia
Interventions
gene expression analysis, molecular genetic technique, polymorphism analysis, protein expression analysis, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Results available

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

NCT00069160
View directory record Official record
Conditions
Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms
Interventions
docetaxel, tariquidar, 99mTc-sestamibi imaging
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Phase 1 Interventional

Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia

NCT00003003
View directory record Official record
Conditions
Leukemia
Interventions
sargramostim, mitomycin C, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Phase 4 Interventional Results available

Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization

NCT03118232
View directory record Official record
Conditions
Hospitalization, Infection
Interventions
Chlorhexidine gluconate (CHG), Iodophor (10% povidone-iodine)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
13,952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
28
States / cities
Anaheim, California • Bellflower, California • Capistrano Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization

NCT03063437
View directory record Official record
Conditions
Antibiotic Resistant Strain
Interventions
Encapsulated fecal microbiota preparation, Encapsulated placebo
Biological
Lead sponsor
Microbiome Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Phase 2 Interventional

Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer

NCT00001493
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
peripheral blood progenitor cells carrying MDR1
Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 11:05 AM EDT
Active, not recruiting No phase listed Observational

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

NCT05388474
View directory record Official record
Conditions
HIV Infections, Multi-Antiviral Resistance
Interventions
No ibalizumab or Pre-ibalizumab treatment, On ibalizumab treatment
Other · Biological
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
36
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

NCT00685360
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
Interventions
Delamanid, Optimized Background Regimen (OBR), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Jul 23, 2026, 11:05 AM EDT
Completed No phase listed Observational

Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn

NCT02653157
View directory record Official record
Conditions
Multi-drug Resistant Gram-negative Bacilli Colonization
Interventions
MDR-GNB
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jul 23, 2026, 11:05 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

NCT06925321
View directory record Official record
Conditions
Invasive Mold Infections
Interventions
Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 11:05 AM EDT
Completed No phase listed Observational

A Comparison of Two Anti-HIV Treatment Plans

NCT00005915
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
21
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Phase 1 Interventional

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

NCT00256191
View directory record Official record
Conditions
Neoplasms, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
TPI 287 Injection
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 14, 2007 · Synced Jul 23, 2026, 11:05 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

NCT04150068
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

NCT00054717
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
96
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Jul 23, 2026, 11:05 AM EDT
Terminated Phase 1 Interventional

FMT for MDRO Colonization After Infection in Renal Transplant Recipients

NCT02922816
View directory record Official record
Conditions
Infection Due to Resistant Organism
Interventions
Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling, Fasting
Biological · Procedure · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Jul 23, 2026, 11:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study of 18F Fluoropaclitaxel (FPAC)

NCT00572598
View directory record Official record
Conditions
Breast Cancer
Interventions
4- [F-18] fluoropaclitaxel
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Jul 23, 2026, 11:05 AM EDT
Recruiting No phase listed Observational

Training Protocol on the Natural History of Tuberculosis

NCT01212003
View directory record Official record
Conditions
Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis, Tuberculosis, Extensively Drug-Resistant Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 11:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Point Prevalence Study of Multidrug-Resistant Organism Carriage by Healthcare Personnel

NCT01952158
View directory record Official record
Conditions
Multidrug Resistance
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 23, 2026, 11:05 AM EDT
Completed No phase listed Observational

Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

NCT01004965
View directory record Official record
Conditions
Leukemia
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
46
States / cities
San Diego, California • Lewes, Delaware • Newark, Delaware + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jul 23, 2026, 11:05 AM EDT
Terminated No phase listed Observational

Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali

NCT01381757
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Mycobacterium Tuberculous, Antitubercular Agents, Tuberculosis, Mulutidrug-Resistant, Extensively Drug-Resistant, Extensibely Drug-Resistant Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 23, 2026, 11:05 AM EDT